Flavonoid metabolite 3-(3-hydroxyphenyl)propionic acid formed by human microflora decreases arterial blood pressure in rats

Molecular Nutrition and Food Research

Volumn 60, Issue 5, 2016, Pages 981-991

  Najmanová, Iveta ^a   Pourová, Jana ^a   Vopršalová, Marie ^a   Pilařová, Veronika ^a   Semecký, Vladimír ^a   Nováková, Lucie ^a   Mladěnka, Přemysl ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Blood pressure; Flavonoid; Metabolite; Phenolic; Quercetin; Rat; Vascular

Indexed keywords

3-HYDROXYPHENYLPROPIONIC ACID; FLAVONOID; PHENOL DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL; ARTERIAL PRESSURE; DRUG EFFECTS; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INTESTINE FLORA; MALE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; ARTERIAL PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLAVONOIDS; GASTROINTESTINAL MICROBIOME; HEMODYNAMICS; HUMANS; IN VITRO TECHNIQUES; LINEAR MODELS; MALE; PHENOLS; PROPIONATES; RATS; RATS, INBRED SHR; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84959377741     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500761     Document Type: Article

References (41)

1. Galindo, P., Gonzalez-Manzano, S., Zarzuelo, M. J., Gomez-Guzman, M. et al., Different cardiovascular protective effects of quercetin administered orally or intraperitoneally in spontaneously hypertensive rats. Food Funct. 2012, 3, 643-650.
2. Mladenka, P., Zatloukalova, L., Filipsky, T., Hrdina, R., Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic. Biol. Med. 2010, 49, 963-975.
3. Johnson, S. A., Figueroa, A., Navaei, N., Wong, A. et al., Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. J. Acad. Nutr. Diet. 2015, 115, 369-377.
4. Novotny, J. A., Baer, D. J., Khoo, C., Gebauer, S. K., Charron, C. S., Cranberry juice consumption lowers markers of cardiometabolic risk, including blood pressure and circulating C-reactive protein, triglyceride, and glucose concentrations in adults. J. Nutr. 2015, 145, 1185-1193.
5. Ellinger, S., Reusch, A., Stehle, P., Helfrich, H. P., Epicatechin ingested via cocoa products reduces blood pressure in humans: a nonlinear regression model with a Bayesian approach. Am. J. Clin. Nutr. 2012, 95, 1365-1377.
6. Edwards, R. L., Lyon, T., Litwin, S. E., Rabovsky, A. et al., Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 2007, 137, 2405-2411.
7. Egert, S., Bosy-Westphal, A., Seiberl, J., Kurbitz, C. et al., Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 2009, 102, 1065-1074.
8. Dower, J. I., Geleijnse, J. M., Gijsbers, L., Zock, P. L. et al., Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial. Am. J. Clin. Nutr. 2015, 101, 914-921.
9. Williamson, G., The use of flavonoid aglycones in in vitro systems to test biological activities: based on bioavailability data, is this a valid approach? Phytochem. Rev. 2002, 1, 215-222.
10. Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P., Tognolini, M. et al., Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox. Signal. 2013, 18, 1818-1892.
11. Chirumbolo, S., Role of quercetin in vascular physiology. Can. J. Physiol. Pharmacol. 2012, 90, 1652-1657.
12. Gormaz, J. G., Quintremil, S., Rodrigo, R., Cardiovascular disease: a target for the pharmacological effects of quercetin. Curr. Top. Med. Chem. 2015, 15, 1735-1742.
13. Schneider, H., Schwiertz, A., Collins, M. D., Blaut, M., Anaerobic transformation of quercetin-3-glucoside by bacteria from the human intestinal tract. Arch. Microbiol. 1999, 171, 81-91.
14. Rechner, A. R., Smith, M. A., Kuhnle, G., Gibson, G. R. et al., Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radic. Biol. Med. 2004, 36, 212-225.
15. Braune, A., Gutschow, M., Engst, W., Blaut, M., Degradation of quercetin and luteolin by Eubacterium ramulus. Appl. Environ. Microbiol. 2001, 67, 5558-5567.
16. Serra, A., Macià, A., Romero, M.-P., Reguant, J. et al., Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem. 2012, 130, 383-393.
17. Graefe, E. U., Derendorf, H., Veit, M., Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. 1999, 37, 219-233.
18. Olthof, M. R., Hollman, P. C., Buijsman, M. N., van Amelsvoort, J. M., Katan, M. B., Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J. Nutr. 2003, 133, 1806-1814.
19. Sawai, Y., Kohsaka, K., Nishiyama, Y., Ando, K., Serum concentrations of rutoside metabolites after oral administration of a rutoside formulation to humans. Arzneimittelforschung 1987, 37, 729-732.
20. Loke, W. M., Hodgson, J. M., Proudfoot, J. M., McKinley, A. J. et al., Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am. J. Clin. Nutr. 2008, 88, 1018-1025.
21. Najmanova, I., Voprsalova, M., Mladenka, P., Vasodilatory activity of human quercitin metabolites. Free Radic. Biol. Med. 2014, 75(Suppl 1), S43 (abstract).
22. Kass, D. A., Maughan, W. L., Guo, Z. M., Kono, A. et al., Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation 1987, 76, 1422-1436.
23. Weiss, J. L., Frederiksen, J. W., Weisfeldt, M. L., Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J. Clin. Invest. 1976, 58, 751-760.
24. Huxley, R. R., Neil, H. A., The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur. J. Clin. Nutr. 2003, 57, 904-908.
25. Jimenez, R., Lopez-Sepulveda, R., Romero, M., Toral, M. et al., Quercetin and its metabolites inhibit the membrane NADPH oxidase activity in vascular smooth muscle cells from normotensive and spontaneously hypertensive rats. Food Funct. 2015, 6, 409-414.
26. Duarte, J., Perez Vizcaino, F., Utrilla, P., Jimenez, J. et al., Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen. Pharmacol. 1993, 24, 857-862.
27. Lodi, F., Jimenez, R., Moreno, L., Kroon, P. A. et al., Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis 2009, 204, 34-39.
28. Galindo, P., Rodriguez-Gomez, I., Gonzalez-Manzano, S., Duenas, M. et al., Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation. PLoS One 2012, 7, e32673.
29. Terao, J., Murota, K., Kawai, Y., Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct. 2011, 2, 11-17.
30. Perez, A., Gonzalez-Manzano, S., Jimenez, R., Perez-Abud, R. et al., The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity. Pharmacol. Res. 2014, 89, 11-18.
31. Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A. et al., Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res. 1998, 21, 17-23.
32. Larrosa, M., Luceri, C., Vivoli, E., Pagliuca, C. et al., Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models. Mol. Nutr. Food Res. 2009, 53, 1044-1054.
33. Semaming, Y., Pannengpetch, P., Chattipakorn, S. C., Chattipakorn, N., Pharmacological properties of protocatechuic acid and its potential roles as complementary medicine. Evid. Based Complement. Alternat. Med. 2015, 2015, 593902.
34. Rechner, A. R., Kuhnle, G., Bremner, P., Hubbard, G. P. et al., The metabolic fate of dietary polyphenols in humans. Free Radic. Biol. Med. 2002, 33, 220-235.
35. Cova, D., Deangelis, L., Giavarini, F., Palladini, G., Perego, R., Pharmacokinetics and metabolism of oral diosmin in healthy-volunteers. Int. J. Clin. Pharm. Th. 1992, 30, 29-33.
36. Gao, K., Xu, A., Krul, C., Venema, K. et al., Of the major phenolic acids formed during human microbial fermentation of tea, citrus, and soy flavonoid supplements, only 3, 4-dihydroxyphenylacetic acid has antiproliferative activity. J. Nutr. 2006, 136, 52-57.
37. Bazzocco, S., Mattila, I., Guyot, S., Renard, C. M., Aura, A. M., Factors affecting the conversion of apple polyphenols to phenolic acids and fruit matrix to short-chain fatty acids by human faecal microbiota in vitro. Eur. J. Nutr. 2008, 47, 442-452.
38. Aura, A. M., Mattila, I., Seppanen-Laakso, T., Miettinen, J. et al., Microbial metabolism of catechin stereoisomers by human faecal microbiota: comparison of targeted analysis and a non-targeted metabolomics method. Phytochem. Lett. 2008, 1, 18-22.
39. Rios, L. Y., Gonthier, M. P., Remesy, C., Mila, I. et al., Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects. Am. J. Clin. Nutr. 2003, 77, 912-918.
40. Luo, L. F., Wu, W. H., Zhou, Y. J., Yan, J. et al., Antihypertensive effect of Eucommia ulmoides Oliv. extracts in spontaneously hypertensive rats. J. Ethnopharmacol. 2010, 129, 238-243.
41. Matouk, A. I., Taye, A., Heeba, G. H., El-Moselhy, M. A., Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ. Toxicol. Pharmacol. 2013, 36, 443-450.